Cholesterol biosynthesis pathway enzyme

Cholesterol biosynthesis pathway enzymes are a group of metabolic enzymes responsible for the multi-step conversion of acetyl-CoA into cholesterol through the mevalonate pathway. This process involves more than 20 enzymatic reactions occurring primarily in the liver and intestines but also in other tissues such as brain and adrenal glands. Key regulatory steps include those catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), which is the primary target of statin drugs, as well as squalene synthase and squalene monooxygenase—both considered rate-limiting points in the pathway[6][3][8]. The final stages involve lanosterol being converted to cholesterol via either the Bloch or Kandutsch–Russell pathways, utilizing specific terminal enzymes such as 24-dehydroxysterol reductase (DHCR24) and 7-dehydrocholesterol reductase (DHCR7)[8]. These enzymes are essential not only for maintaining cell membrane integrity but also serve as precursors for steroid hormones, bile acids, vitamin D, and signaling oxysterols. Dysregulation or overactivity can contribute to diseases including cardiovascular disorders due to hypercholesterolemia, certain cancers where increased flux through this pathway supports tumor growth[6], neurodegenerative diseases linked to altered sterol homeostasis, and metabolic syndromes. Therapeutic targeting focuses on inhibiting key regulatory steps—most notably HMG-CoA reductase—with drugs like statins that lower plasma cholesterol levels by blocking endogenous synthesis. Other drug classes target different steps within this cascade; however, inhibition may lead to side effects related both directly to reduced cholesterol availability or indirectly via impaired production of downstream metabolites such as steroid hormones. Note on correctness: The term "Cholesterol biosynthesis pathway enzymes" refers collectively to a family/group rather than a single molecular entity; thus it is not a canonical name suitable for structured databases focused on individual targets. For structured data purposes each individual enzyme should be listed separately under its own canonical name—for example "3-hydroxy-3-methylglutaryl-coenzyme A reductase" or "Squalene monooxygenase"[1][5].

Other names

Cholesterol synthesis enzymeMevalonate pathway enzymeSterol biosynthetic enzyme

Inhibition of rate-limiting enzymes to reduce cholesterol synthesis (e.g., statins inhibit HMG-CoA reductase)[8][3] - Inhibition of downstream enzymes to block sterol intermediate formation or conversion[6][1]